Neuroscience Catalyst to Focus on Mood Disorders and Alzheimer's Disease
TORONTO, Sept. 8, 2014 /CNW/ - Janssen Inc. (Janssen) today announced it
has signed an agreement, facilitated by the Johnson & Johnson
Innovation center in California, with the University of Toronto's
Centre for Collaborative Drug Research (CCDR) to form an open-source
collaboration focused on novel therapeutic approaches to the treatment
and management of mood disorders and Alzheimer's disease.
The research project, called Neuroscience Catalyst, represents an innovative collaboration between industry, academia and
the research community. Neuroscience Catalyst will help identify medical and scientific opportunities in early-stage
development, which can progress to clinical treatment for brain
"Collaborating with the University of Toronto to advance the study of
mood disorders and Alzheimer's disease demonstrates Janssen's ongoing
commitment to investing in early-stage research and meeting unmet
patient needs," said Paul Kershaw, M.D., F.A.A.N., Vice President,
Medical Affairs, Janssen Canada. "This agreement supports medical
research and development in Canada, which is fundamental to the
sustainability of our healthcare system."
Participating researchers will have access to cutting-edge drug
discovery tools and information, as well as access to Johnson & Johnson
Innovation and Janssen R&D resources, thereby facilitating research
progress. The University of Toronto will co-fund the research and
create a structure for soliciting and evaluating proposals from
researchers, including from other academic hospitals and research
institutions, as well as the Centre for Addiction and Mental Health
"We are delighted to collaborate with the University of Toronto on the Neuroscience Catalyst program which deepens our commitment to the translation of exciting new
concepts in the field of Neuroscience drug discovery research," said
Husseini K. Manji, M.D., FRCPC, Global Therapeutic Area Head,
Neuroscience, Janssen R&D, LLC. "Working with some of the world's best
neuroscience researchers based in Canada, this collaboration with will
further our understanding of mood disorders such as depression as well
as Alzheimer's disease."
Representatives from the University of Toronto and Janssen will form a
Joint Steering Committee to review research proposals and provide
recommendations to the CCDR for external review and approval. The
Committee will also provide scientific oversight, advice on funded
research and will monitor the progress of and review results arising
from the research. The first call for proposals will be issued in
"As its name suggests, this collaboration will be a catalyst for the
discovery of new therapeutics targeted at mental health and
neurodegenerative disorders," said Professor Ruth Ross, Ph.D.,
Director, Centre for Collaborative Drug Research, Chair, Department of
Pharmacology and Toxicology, University of Toronto and Senior
Scientist, Campbell Family Mental Health Research Institute, CAMH.
"Conditions such as dementia and depression affect hundreds of millions
worldwide, and that number is rising. By working together in an open
innovation partnership, we can conduct the basic research needed to
identify new therapeutic options for patients."
Reza Moridi, Ontario Minister of Research and Innovation added,
"Partnerships between talented researchers and innovative companies
lead to advances beyond what any of us could accomplish working alone.
I applaud the collaboration between the University of Toronto, Janssen
and Johnson & Johnson Innovation. Thanks to the visionary work of these
organizations, Ontario will continue to lead life sciences discoveries
that result in better mental health and quality of life for everyone."
About Johnson & Johnson Innovation
Johnson & Johnson Innovation, LLC focuses on accelerating early-stage
innovation worldwide and forming collaborations between entrepreneurs
and Johnson & Johnson's global healthcare businesses. Johnson & Johnson
Innovation provides scientists, entrepreneurs and emerging companies
one-stop access to science and technology experts who can facilitate
collaborations across the pharmaceutical, medical device and
diagnostics and consumer companies of Johnson & Johnson. Johnson &
Johnson Innovation includes local deal-making capabilities with the
flexibility to adapt deal structures to match early-stage opportunities
and establish novel collaborations that speed development of
innovations to solve unmet needs in patients.
Johnson & Johnson Innovation facilitates early stage collaborations
across the Johnson & Johnson Family of Companies. For more information
please visit: www.jnjinnovation.com.
About Janssen Inc.
Janssen Inc. is one of the Janssen Pharmaceutical Companies of Johnson &
Johnson, which are dedicated to addressing and solving some of the most
important unmet medical needs in oncology, immunology, neuroscience,
infectious diseases and vaccines, and cardiovascular and metabolic
diseases. Driven by our commitment to patients, we bring innovative
products, services and solutions to people throughout the world. For
more information please visit: www.janssen.ca.
SOURCE: Janssen Inc.
For further information: